Northpointe Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Northpointe Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-163,324	Closed	-$7.41M	–	199
2017 Q1	$7.41M	Sell	163,324 -42,199	-21%	-$1.88M	0.81%	41
2016 Q4	$7.78M	Sell	205,523 -70,191	-25%	-$2.65M	0.77%	44
2016 Q3	$10.4M	Sell	275,714 -206,055	-43%	-$4.54M	1.08%	27
2016 Q2	$8.48M	Buy	481,769 +189,629	+65%	+$3.07M	1%	32
2016 Q1	$3.55M	Sell	292,140 -150,985	-34%	-$2.39M	0.44%	83
2015 Q4	$7.86M	Hold	443,125	–	–	1.03%	26
2015 Q3	$7.86M	Sell	443,125 -591,275	-57%	-$10.7M	1.02%	26
2015 Q2	$18.3M	Buy	1,034,400 +706,488	+215%	+$13M	2.15%	2
2015 Q1	$10.3M	Buy	+327,912	New	+$9.5M	1.11%	22

Other funds holding AERI

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Northpointe Capital's AERI Position: Q2 2017 in Review

Northpointe Capital sold out of Aerie Pharmaceuticals (AERI) in Q2 2017, closing a stake of 163,324 shares — an estimated $7.41M sold.

Northpointe Capital first reported a position in AERI in Q1 2015 and held it in 9 quarters. The position peaked at $18.3M in Q2 2015. 172 funds tracked by Wall St. Rank hold AERI as of Q2 2017.

Northpointe Capital reported no remaining Aerie Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Northpointe Capital sold 163,324 Aerie Pharmaceuticals shares in Q2 2017, an estimated $7.41M.
Northpointe Capital first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 9 quarters.
Northpointe Capital's Aerie Pharmaceuticals position peaked at $18.3M in Q2 2015.
172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2017.

Based on Northpointe Capital's 13F filing for Q2 2017, filed 3 Aug 2017.